Dementia agitation drug trial halted after just 5 patients
NCT ID NCT05276830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reliable conclusions about whether the drug works or is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dexmedetomidine (BXCL501) sublingual film
What this could lead to
If it worked, this could offer a fast-acting option to calm agitation in people with dementia, reducing distress for patients and caregivers.
What could go wrong
The trial was terminated early with only 5 participants, so results are very limited. It is unclear if the drug is safe or effective for this use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BioXcel Clinical Research Site
Toms River, New Jersey, 08755, United States
-
Bioxcel Clinical Research Site
North Miami, Florida, 33161, United States
-
Bioxcel Clinical Research Site
Springfield, Massachusetts, 01103, United States